3 ms·

There's another risk besides the obvious antibody-dependent enhancement problem: this vaccine could change your response to an official COVID-19 vaccine that yo

There's another risk besides the obvious antibody-dependent enhancement problem: this vaccine could change your response to an official COVID-19 vaccine that you might want to get later. You might be left with enough immune response to squash another vaccine that's trying to help you, but not enough to stop the actual disease. The fact that they're going for mucosal immunity, making their vaccine different from the leading official candidates, makes this bad interaction less likely. Still, I think it's important to mention.

gus_massa 6y ago
The antibody-dependent enhancement problem is mentioned in the article, but I think it needs a longer explanation. From https://en.wikipedia.org/wiki/Antibody-dependent_enhancement https://en.wikipedia.org/wiki/Antibody-dependent_enhancement > Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, and sometimes also its replication.[1] This phenomenon—which leads to both increased infectivity and virulence—has been observed with mosquito-borne flaviviruses such as Dengue virus, Yellow fever virus and Zika virus,[2][3] with HIV, and with coronaviruses.[4] where [4] is https://www.ft.com/content/f1b25b41-f3cf-4a73-ba8f-582385bc2eeb https://www.ft.com/content/f1b25b41-f3cf-4a73-ba8f-582385bc2... that says about SARS (2003): > Some animals that were given experimental Sars vaccines suffered more severe lung inflammation than unvaccinated animals when subsequently infected. Those trials stopped and there is still no effective Sars vaccine.
- robocat 6y ago
  From confiks answer: They argue that antibody-dependent enhancement (ADE) specifically is less likely because the immune response of the intranasal vaccine is limited to the mucosal tissue [2]. [1] https://radvac.org/wp-content/uploads/2020/07/White-Paper-SA.. https://radvac.org/wp-content/uploads/2020/07/White-Paper-SA.... [2] See [1] page 6

gus_massa 6y ago

The antibody-dependent enhancement problem is mentioned in the article, but I think it needs a longer explanation. From https://en.wikipedia.org/wiki/Antibody-dependent_enhancement https://en.wikipedia.org/wiki/Antibody-dependent_enhancement > Antibody-dependent enhancement (ADE), sometimes less precisely called immune enhancement or disease enhancement, is a phenomenon in which binding of a virus to suboptimal antibodies enhances its entry into host cells, and sometimes also its replication.[1] This phenomenon—which leads to both increased infectivity and virulence—has been observed with mosquito-borne flaviviruses such as Dengue virus, Yellow fever virus and Zika virus,[2][3] with HIV, and with coronaviruses.[4] where [4] is https://www.ft.com/content/f1b25b41-f3cf-4a73-ba8f-582385bc2eeb https://www.ft.com/content/f1b25b41-f3cf-4a73-ba8f-582385bc2... that says about SARS (2003): > Some animals that were given experimental Sars vaccines suffered more severe lung inflammation than unvaccinated animals when subsequently infected. Those trials stopped and there is still no effective Sars vaccine.

robocat 6y ago
From confiks answer: They argue that antibody-dependent enhancement (ADE) specifically is less likely because the immune response of the intranasal vaccine is limited to the mucosal tissue [2]. [1] https://radvac.org/wp-content/uploads/2020/07/White-Paper-SA.. https://radvac.org/wp-content/uploads/2020/07/White-Paper-SA.... [2] See [1] page 6